Literature DB >> 12705971

Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation.

Lutz Bräutigam1, Jens U Nefflen, Gerd Geisslinger.   

Abstract

The validation of a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for the determination of the selective cyclooxygenase-2 inhibitor etoricoxib in human plasma with phenazone as internal standard is described. The plasma samples were extracted by solid-phase extraction using polymer-based cartridges. Chromatography was carried out on a short, narrow bore RP C(18) column (30x2 mm). Detection was achieved by a Sciex API 3000 triple quadrupole mass spectrometer equipped with a turbo ion spray source working in positive ion mode. The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1. The analytical method was validated over the concentration range 0.2-200 ng/ml. The limit of quantification was 0.2 ng/ml. The method is applicable to pharmacokinetic studies in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12705971     DOI: 10.1016/s1570-0232(03)00034-5

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty.

Authors:  Annika Piirainen; Merja Kokki; Heidi Hautajärvi; Marko Lehtonen; Hannu Miettinen; Kari Pulkki; Veli-Pekka Ranta; Hannu Kokki
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

2.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

Review 3.  Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.

Authors:  Jody K Takemoto; Jonathan K Reynolds; Connie M Remsberg; Karina R Vega-Villa; Neal M Davies
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Analysis of Different Methods of Extracting NSAIDs in Biological Fluid Samples for LC-MS/MS Assays: Scoping Review.

Authors:  Viviane Silva Siqueira Sandrin; Gabriela Moraes Oliveira; Giovana Maria Weckwerth; Nelson Leonel Del Hierro Polanco; Flávio Augusto Cardoso Faria; Carlos Ferreira Santos; Adriana Maria Calvo
Journal:  Metabolites       Date:  2022-08-16

5.  Fast and Sensitive HPLC-ESI-MS/MS Method for Etoricoxib Quantification in Human Plasma and Application to Bioequivalence Study.

Authors:  Gabriel Onn Kit Loh; Emily Yii Ling Wong; Yvonne Tze Fung Tan; Siew Chyee Heng; Mardiana Saaid; Kit Yee Cheah; Nurul Diyana Mohd Sali; Nair Damenthi; Sharon Shi Min Ng; Long Chiau Ming; Kok Khiang Peh
Journal:  Molecules       Date:  2022-09-04       Impact factor: 4.927

6.  Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

Authors:  Bertold Renner; Josef Zacher; Asokumar Buvanendran; Gerrit Walter; Jochen Strauss; Kay Brune
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-06       Impact factor: 3.000

7.  Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief.

Authors:  B Renner; G Walter; J Strauss; M F Fromm; J Zacher; K Brune
Journal:  Eur J Pain       Date:  2011-12-19       Impact factor: 3.931

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.